Plain-English translation of NCT07371468 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial of , a new type of treatment that uses immune cells to help control overactive immune responses in autoimmune rheumatic diseases. Researchers will test different doses to find the safest and most effective amount, and monitor how your body processes and responds to the medication. The goal is to understand whether this new approach is safe, well-tolerated, and could help people with conditions like lupus, rheumatoid arthritis, and related diseases.
Current treatments for autoimmune rheumatic diseases don't work well enough for everyone, and some people experience serious side effects. This medication takes a different approach by targeting specific immune cells, which researchers hope could offer a better, safer way to control these diseases.
You likely qualify if…
You likely don't qualify if…
The study has two phases. In the first phase, participants receive different doses of the medication to find the right starting amount and to confirm it is safe. In the second phase, other participants receive the medication at doses determined from the first phase. Throughout the study, you will have regular clinic visits and blood tests to monitor your safety, how your body processes the medication, and whether it helps your symptoms.
AI-generated summary from trial data · Jun 29, 2026 · Not medical advice
Argentina
Brazil
France